These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 39376478)

  • 1. Improving Adherence and Reducing Health Care Costs Through Blister-Packaging: An Economic Model for a Commercially Insured Health Plan.
    Borrelli EP; Saad P; Barnes NE; Dumitru D; Lucaci JD
    Clinicoecon Outcomes Res; 2024; 16():733-745. PubMed ID: 39376478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the economic impact of blister-packaging on medication adherence and health care costs for a Medicare Advantage health plan.
    Borrelli EP; Saad P; Barnes N; Dumitru D; Lucaci JD
    J Manag Care Spec Pharm; 2024 Dec; 30(12):1442-1454. PubMed ID: 39258999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of the ExactCare medication care management model on adherence, health care utilization, and costs.
    Shetty KD; Chen AY; Rose AJ; Liu HH
    J Manag Care Spec Pharm; 2021 May; 27(5):574-585. PubMed ID: 33560167
    [No Abstract]   [Full Text] [Related]  

  • 4. Associations of Renin-Angiotensin System Antagonist Medication Adherence and Economic Outcomes Among Commercially Insured US Adults: A Retrospective Cohort Study.
    Campbell PJ; Axon DR; Taylor AM; Pickering M; Black H; Warholak T; Chinthammit C
    J Am Heart Assoc; 2020 Sep; 9(17):e016094. PubMed ID: 32844732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Budget Impact of Increased Use of Mirabegron, A Novel Treatment for Overactive Bladder.
    Perk S; Wielage RC; Campbell NL; Klein TM; Perkins A; Posta LM; Yuran T; Klein RW; Ng DB
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1072-84. PubMed ID: 27579830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year examination of utilization and drug cost outcomes associated with benefit design changes including reference pricing for proton pump inhibitors in a state employee health plan.
    Johnson JT; Neill KK; Davis DA
    J Manag Care Pharm; 2011 Apr; 17(3):200-12. PubMed ID: 21434697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
    Kangethe A; Polson M; Lord TC; Evangelatos T; Oglesby A
    J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs.
    Peasah SK; Liu Y; Krohe S; Campbell V; Lee C; Mathur A; Stevenson H; Manolis C; Good CB
    J Manag Care Spec Pharm; 2024 Jan; 30(1):43-51. PubMed ID: 38153862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing adherence and persistence across 6 chronic medication classes.
    Yeaw J; Benner JS; Walt JG; Sian S; Smith DB
    J Manag Care Pharm; 2009; 15(9):728-40. PubMed ID: 19954264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacy benefit spending on oral chemotherapy drugs.
    Curtiss FR
    J Manag Care Pharm; 2006 Sep; 12(7):570-7. PubMed ID: 16981802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost and utilization of behavioral health medications associated with rescission of an exemption for prior authorization for severe and persistent mental illness in the Vermont Medicaid Program.
    Simeone JC; Marcoux RM; Quilliam BJ
    J Manag Care Pharm; 2010 Jun; 16(5):317-28. PubMed ID: 20518584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic and utilization outcomes of medication management at a large Medicaid plan with disease management pharmacists using a novel artificial intelligence platform from 2018 to 2019: a retrospective observational study using regression methods.
    Kessler S; Desai M; McConnell W; Jai EM; Mebine P; Nguyen J; Kiroyan C; Ho D; Von Schweber E; Von Schweber L
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1186-1196. PubMed ID: 34032130
    [No Abstract]   [Full Text] [Related]  

  • 15. Budget impact analysis of increasing prescription of renin-angiotensin system inhibitors drugs to standard anti-hypertensive treatments in patients with diabetes and hypertension in a hypothetical cohort of Malaysian population.
    Mohd-Tahir NA; Li SC
    PLoS One; 2019; 14(2):e0212832. PubMed ID: 30817790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health plan budget impact analysis for pimecrolimus.
    Chang J; Sung J
    J Manag Care Pharm; 2005; 11(1):66-73. PubMed ID: 15667234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
    Bly CA; Molife C; Brown J; Tawney MK; Carter GC; Cinfio FN; Klein RW
    J Manag Care Spec Pharm; 2018 Jun; 24(6):534-543. PubMed ID: 29799326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of tetanus, diphtheria, and acellular pertussis (Tdap) vaccine use in wound management on health care costs and pertussis cases.
    Talbird SE; Graham J; Mauskopf J; Masseria C; Krishnarajah G
    J Manag Care Spec Pharm; 2015 Jan; 21(1):88-99, 99a-c. PubMed ID: 25562776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.
    Martin A; Bessonova L; Hughes R; Doane MJ; O'Sullivan AK; Snook K; Cichewicz A; Weiden PJ; Harvey PD
    Adv Ther; 2022 Sep; 39(9):3933-3956. PubMed ID: 35844007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.